Quarterly ResultMay 7, 2026, 04:28 PM
Myomo Q1 Revenue Up 2.9% to $10.1M; Net Loss Narrows to $3.0M
AI Summary
Myomo, Inc. reported a 2.9% increase in revenue to $10.1 million for Q1 2026, compared to $9.8 million in Q1 2025. The company's net loss narrowed significantly to $3.0 million, or $0.07 per share, from $3.5 million, or $0.08 per share, in the prior year. Operating cash outflow improved to $2.2 million from $2.7 million. The company believes its current cash and investments will fund operations for at least the next twelve months.
Key Highlights
- Q1 2026 revenue increased 2.9% to $10.1 million from $9.8 million in Q1 2025.
- Net loss narrowed to $3.0 million ($0.07 per share) in Q1 2026 from $3.5 million ($0.08 per share) in Q1 2025.
- Loss from operations improved to $3.2 million in Q1 2026 from $3.5 million in Q1 2025.
- Net cash used in operating activities decreased to $2.2 million in Q1 2026 from $2.7 million in Q1 2025.
- Direct to patient revenue was $7.2 million in Q1 2026, while clinical/medical providers revenue was $2.9 million.
- US revenue accounted for 80% of total revenue in Q1 2026, with Germany contributing 20%.
- Cash and cash equivalents stood at $11.4 million as of March 31, 2026.
- The company has $17.5 million in committed capital from a Loan and Security Agreement, with $12.5 million funded.
Price Impact
More from MYO